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Abstract Liver abnormalities have been reported to
occur in up to 20 % of patients on a long-term therapy with
the tricyclic antidepressant drug imipramine (IMI). The
mechanism involved in this IMI-induced process is
unknown but a contribution of oxidative stress is highly
likely. Chronic mild stress (CMS) is widely used for
modeling depressive-like behavior in rats. In the present
study, we examined the effects of CMS and chronic IMI
treatment, applied alone or in combination, on the levels of
oxidative stress markers, such as reactive oxygen species
(ROS), malondialdehyde (MDA), non-protein sulfhydryl
groups, and sulfane sulfur as well as on activities of key
antioxidant enzymes: catalase (CAT), glutathione peroxi-
dase (GPx), and superoxide dismutase in the rat liver.
Administration of IMI for 5 weeks to rats subjected to
CMS resulted in a gradual significant reduction of
anhedonia measured by sucrose intake, in a majority of
animals (CMS IMI-reactive, CMS IMI-R), although about
20 % of rats did not respond to the IMI treatment (CMS
IMI non-reactive, CMS IMI-NR). CMS-induced hepatic
oxidative stress, estimated by increased ROS and MDA
concentrations, was not prevented by the IMI administra-
tion, moreover, in CMS IMI-NR animals, the level of the
marker of lipid peroxidation, i.e., MDA was increased in
comparison to CMS-subjected rats and activity of antiox-
idant enzymes (GPx and CAT) was decreased compared to
IMI-treated rats. The clinical significance of this observa-
tion remains to be established.
Keywords Chronic mild stress  Depression 
Imipramine  Liver  Oxidative stress
Introduction
Clinical reports suggest a close relationship between
stressors, particularly those of long duration, and liver
diseases, such as hepatic inflammation, that is proposed to
be caused by reactive oxygen species (ROS). The liver
exhibits one of the highest antioxidant enzyme capacities in
the body due to its major metabolic roles including
glycogen storage, decomposition of red blood cells, plasma
protein synthesis, detoxification, and others (Navarro-
Arevalo and Sanchez-Del-Pino 1998). This organ also
plays indispensable role in the adaptive response to neu-
roendocrine stress, when its anabolic activity provides
energy-rich compounds, such as glucose and lipids, nec-
essary for adaptation of the body.
Tricyclic/tetracyclic antidepressant drugs are known for
their hepatotoxicity but only few cases were reported lately,
possibly due to their relatively infrequent current use in the
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USA and Europe (Sedky et al. 2012; El-Hage et al. 2013).
Causality is not well established due to concurrent admin-
istration of other drugs and/or underlying liver disease
(DeSanty and Amabile 2007). Patients treated with tricyclic
drugs are at a greater risk of liver damage than those
receiving newer antidepressant agents (Lucena et al. 2003).
Imipramine (IMI) is among the antidepressants associated
with a greater risk of hepatotoxicity since the drug was
introduced to the therapy in 1957 (Moskovitz et al. 1982;
Voican et al. 2014). IMI is a dibenzazepine-derived tricyclic
antidepressant which acts by serotonin and norepinephrine
reuptake inhibition within the synaptic cleft in the central
nervous system. IMI is still widely used, more than 1 million
prescriptions being filled yearly. IMI is indicated not only
for therapy of depression but also is used for childhood
enuresis. Liver test abnormalities have been reported to
occur occasionally in up to 20 % of patients on a long-term
IMI therapy (Moskovitz et al. 1982). For instance, a pro-
longed cholestatic hepatitis development was described in
an IMI-treated person (Horst et al. 1980). The mechanism by
which IMI causes liver test abnormalities is not known but
probably oxidative stress is involved in this process.
In experimental animals, a chronic mild stress (CMS)
paradigm is considered to be a model of depression and is
widely used for examining the effects of treatment with
antidepressant drugs (Willner 2005). Exposure to CMS
produces a markedly diminished interest in rewarding
stimuli, evidenced by reduced preference for a palat-
able sucrose solution over water (Papp et al. 1991; Kubera
et al. 1996). This represents a disturbance of the ability to
experience pleasure which is suggested to model human
anhedonia, a core symptom of major depression episodes
according to DSM-IV criteria (Diagnostic and Statistical
Manual of Mental Disorders Fourth Edition, American
Psychiatric Association 1994; Willner 2005). Repeated
antidepressant treatments antagonize stress-induced anhe-
donia (Papp and Moryl 1994; Kubera et al. 2001) and also
behavioral passivity in the forced swimming test (Rogó _z
et al. 2009), although in our studies some of us established
that a part of animals did not respond to IMI treatment in
the CMS model of depression (Faron-Górecka et al. 2014).
It is unknown why in some rats exposed to CMS IMI does
not produce a therapeutic effect. It is similar to clinical
situation, when some group of patients does not respond to
antidepressive drugs (El-Hage et al. 2013).
Some recent studies strongly suggested that oxidative
stress plays a significant role in the stress-induced depressive
illness (Khanzode et al. 2003; Sarandol et al. 2007; Lucca
et al. 2009a, b; Maes et al. 2011b; Stefanescu and Ciobica
2012). If so, it is reasonable to think that chronic antide-
pressant treatment paralleled by normalization of depres-
sive-like symptoms would be expected to reverse effects of
oxidative stress. However, since some rats did not respond to
IMI therapy, we hypothesize that chronic administration of
this drug to rats exposed to CMS may differently affect
antioxidant system in responding and non-responding ani-
mals. According to currently available literature, there are
no studies providing the data which may help to relate IMI
treatment resistance to oxidative system dysfunction in the
distinct target tissue, such as the liver.
To check the above-postulated hypothesis, in the present
study, we examined the effects of CMS and chronic IMI
treatment, alone or in combination, on markers of oxidative
stress, such as production of ROS, lipid peroxidation mea-
sured by malondialdehyde (MDA) level, concentrations of
antioxidants, i.e., glutathione (GSH) assessed by non-protein
sulfhydryl groups (NPSH) and sulfane sulfur (SS) in the rat
liver. SS is a labile and highly reactive sulfur in 0 or -1
oxidation state covalently bound to another sulfur atom
formed during the anaerobic cysteine metabolism. It shows
regulatory and more potent antioxidant properties than GSH
(Everett et al. 1994; Iciek and Włodek 2001). To further
characterize severity of oxidative stress in these groups of
rats, the activities of key antioxidant enzymes: catalase
(CAT), glutathione peroxidase (GPx), and superoxide dis-
mutase (SOD) were also determined in the rat liver. We
hope that this set of experiments will shed a new light on a
role of IMI in the treatment of drug-resistant depression.
Materials and Methods
Animals
Behavioral tests were carried out on male Wistar rats
(Charles River, Germany), of initial body weight
220–240 g (about 7 weeks old). The animals were kept
singly housed under standard laboratory conditions with
free access to standard laboratory food and tap water, at
room temperature of 22 C with an artificial day–night
cycle (12/12 h, light on at 8 a.m.). Each experimental
group consisted of 6–8 rats.
All the procedures were carried out in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were granted an approval
from the Bioethics Commission as compliant with Polish
Law. All the experimental procedures were approved by
the Local Bioethics Commission of the Institute of Phar-
macology, Polish Academy of Sciences in Krakow.
Drug
Imipramine hydrochloride (IMI, Sigma-Aldrich, USA) was
obtained commercially, dissolved in sterile 0.9 % NaCl
solution, and injected at a dose of 10 mg/kg b.w. i.p. in a
volume of 1 ml/kg.
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Chronic Mild Stress (CMS) Procedure
Male wistar rats were brought into the laboratory a month
prior to the start of the experiment. The animals were first
trained to consume a 1 % sucrose solution. Training con-
sisted of six 1-h baseline tests once a week in which
sucrose was presented in the home cage following 14-h
periods of food and water deprivation. The sucrose intake
was measured by weighing the bottles before and at the end
of the test and subtraction of results. After the training
period, sucrose consumption was further monitored at
weekly intervals throughout the experiment. On the basis
of their sucrose intakes in the final baseline test, the ani-
mals were divided into two matched groups. One group of
animals was subjected to the CMS procedure for a period
of seven consecutive weeks. Each week the stress regime
consisted of two periods of food or water deprivation, two
periods of 45 cage tilt, two periods of intermittent illu-
mination (lights on and off every 2 h), two periods of
soiled cage (250 ml water in sawdust bedding), one period
of paired housing, two periods of low-intensity strobo-
scopic illumination (150 flashes/min), and three periods of
no stress. All stressors were 10–14 h in duration and were
applied individually and continuously. Control animals
were housed in separate rooms and had no contact with the
stressed animals. They were deprived of food and water for
14 h preceding each sucrose test, but otherwise food and
water were freely available in the home cage.
On the basis of their sucrose intakes following initial
2 weeks of stress, both the stressed and the control groups
were each divided further into matched subgroups, and for
subsequent five weeks they received once daily intraperi-
toneal injections of vehicle (sterile saline, 1 ml/kg b.w.) or
IMI (10 mg/kg b.w.). IMI was administered at approx.
10.00 a.m. and the weekly sucrose tests were carried out
24 h following the last drug injection. Stress was continued
throughout the entire period of treatment. After seven
weeks of stress, sucrose intake was significantly lower in
the stressed animals, but administration of IMI for 5 weeks
to the animals still subjected to CMS resulted in most of
animals in a significant reduction in anhedonia (CMS IMI-
reactive, CMS IMI-R), as measured by sucrose intake,
which remains in agreement with previously published data
(Monleon et al. 1995). About 20 % of animals did not
respond to the imipramine treatment by reversal of stress-
induced sucrose intake deficit and we called this group IMI
non-reactive (CMS IMI non-reactive, CMS IMI-NR).
Chemicals
5,50-Dithiobis-2-nitrobenzoic acid (DTNB), GSH reduced
(GSH), 2-thiobarbituric acid (TBA), GSH reductase (GR),
NADPH, epinephrine (adrenaline), 20,70-dichlorofluorescein
diacetate (DCFH-DA), potassium cyanide (KCN), tri-
chloroacetic acid (TCA) were provided by Sigma Chemical
Co. (St. Louis, MO, USA). Formaldehyde and hydrogen
peroxide (H2O2) were obtained from the Polish Chemical
Reagent Company (P.O.Ch, Gliwice, Poland).
Preparation of Tissue Homogenate
After termination of behavioral procedure (i.e., 2 days after
the final sucrose intake test), rats were killed by decapita-
tion, their livers were dissected and immediately frozen on
dry ice. Then, the tissues were stored at -80 C until
further procedures were applied.
The frozen livers were weighed, and homogenates were
prepared by homogenization of 1 g of the tissue in 4 ml of
0.1 M phosphate buffer, pH 7.4 using an IKA-ULTRA-
TURRAX T8 homogenizer. Liver homogenates were next
used for assay of the activity of antioxidant enzymes (CAT,
GPx, SOD) and some markers of oxidative stress, such as
the levels of ROS, MDA, non-protein sulfhydryl groups
(NPSH corresponding mainly to GSH), and sulfane sulfur.
Determination of Reactive Oxygen Species Level
DCFH-DA was deestrified in homogenates to dichlorohy-
drofluorescein, and was then oxidized to fluorescent
dichlorofluorescein by ROS (Bondy and Guo 1994).
Briefly, 10 ll of a liver homogenate were added to 980 ll
of 0.1 M phosphate buffer (pH 7.4) and 10 ll of 1.25 mM
DCFH-DA in ethanol. Mixtures were incubated at 37 C
for 30 min protected from light and then centrifuged at
12,0009g for 8 min. Fluorescence was measured with
Hitachi F-2000 fluorescence spectrometer at an excitation
of 488 nm and emission of 525 nm. ROS were evaluated
from a standard curve with 10 lM dichlorofluorescein.
Determination of Malondialdehyde Level
The level of MDA as a measure of lipid peroxidation was
determined using the TBA spectrophotometric assay with
1,10,3,30-tetraethoxypropane as a standard (Ohkawa et al.
1979). TBA reacts with some products of lipid peroxida-
tion in acidic environment at increased temperature to form
a pink compound. Briefly, 250 ll of a liver homogenate
were added to 250 ll of distilled water, 500 ll of 15 %
TCA, and 500 ll of 0.37 % TBA. TCA and TBA solutions
were prepared in 0.25 M HCl. The samples were heated in
a boiling water bath for 10 min. After cooling, the samples
were centrifuged at 12,0009g for 10 min. The absorbance
of the supernatant was measured at 535 nm.
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Determination of Non-protein Sulfhydryl Group
Level
The level of NPSH was estimated with DTNB according to
the method described by Sedlak and Lindsay (1968). In this
assay, DTNB is reduced by non-protein sulfhydryl groups
present in TCA extract to yellow 2-nitro-5-mercaptoben-
zoic acid, absorbance of which is measured. For the esti-
mation of NPSH, 0.05 ml of TCA extract and 0.1 ml of
6 mM DTNB were added in succession to 0.85 ml of
0.2 M phosphate buffer pH 8.2, and absorbance was
measured at 412 nm. The total content of non-protein
sulfhydryl groups was determined from a standard curve
for 1 mM GSH.
Determination of Sulfane Sulfur Level
The level of the compounds containing sulfane sulfur was
determined by the method of Wood (1987) based on cold
cyanolysis and colorimetric detection of ferric thiocyanate
complex ion. To 200 ll of liver homogenate, 80 ll of 1 M
NH3, 620 ll of distilled water, and 100 ll of 0.5 M KCN
were added. The samples were incubated at room tem-
perature for 45 min. Then 20 ll of 38 % formaldehyde and
200 ll of Goldstein’s reagent [Fe(NO3) ? HNO3 ? H2O]
were added. After centrifugation at 12,0009g for 10 min,
the absorbance at 460 nm was determined. A standard
curve was prepared with 1 mM KSCN.
Determination of Superoxide Dismutase Activity
SOD activity was measured by a colorimetric assay.
Superoxide radical anion ðO2Þ, the substrate for SOD, was
generated indirectly in the oxidation of epinephrine at
alkaline pH by the action of oxygen. The pink oxidation
product of epinephrine (adrenochrome) was measured
spectrophotometrically at 485 nm (Misra and Fridovich
1972). Briefly, to 875 ll of 50 mM carbonate buffer, pH
10.2, 25 ll of liver homogenate diluted 100-fold and
100 ll of 10 mM epinephrine solution were added. The
absorbance at 485 nm was measured for 3 min. As a
standard 25 ll of SOD solution with known activity was
used.
Determination of Glutathione Peroxidase Activity
Activity of GSH peroxidase was assayed by the method of
Flohe and Gunzler (1984). This method was based on GSH
oxidation by hydrogen peroxide that was catalyzed by GPx.
This reaction yielded GSSG which was then reduced by
GR to GSH at the expanse of NADPH oxidation. NADPH
oxidation caused the decrease in absorbance at 340 nm,
which could be measured spectrophotometrically. To a
thermostated spectrophotometric cuvette kept at 37 C, the
following reagents were added: 600 ll of 0.1 M phosphate
buffer pH 7.0 containing 0.1 mM EDTA, 100 ll of
homogenate diluted 50-fold, 100 ll of GR solution of 2.4
U/ml final activity, 100 ll of 10 mM GSH solution, and
100 ll of 1.5 mM NADPH solution in 0.1 % NaHCO3
solution. The reaction was initiated by the addition of
100 ll of 1.5 mM H2O2 heated to 37 C. Then the decline
in absorbance was measured at 340 nm for 2 min. The
difference between absorbance decrement (DA340/min) in
the homogenate-containing sample and control sample
(without homogenate) was calculated. The difference
between the absorbance change rates is a measure of GPx
activity in the sample.
Determination of Catalase Activity
Catalase activity was determined by the Aebi (1984)
method. Catalase degrades H2O2, which can be measured
directly by the decrease in the absorbance at 240 nm. In
this method, 50 ll of liver homogenate diluted 50-fold was
added to 650 ll of 50 mM phosphate buffer, pH 7.0. The
reaction was initiated by addition of 300 ll of 54 mM
H2O2 and the decrease in absorbance was measured for
1 min at 25 C. A unit of catalase activity was defined as
such amount of the enzyme which decomposed 1 lmol
H2O2 per minute.
Determination of Protein Content
Protein content was assayed by Lowry’s et al. method
(1951), which is based on the reaction of peptide bonds and
aromatic amino acid residues of proteins with Folin–Cio-
calteu reagent (a mixture of phosphotungstic acid and
phosphomolybdic acid) in alkaline environment in the
presence of cupric ions. Copper (II) ions, bound to protein
tyrosine and tryptophan residues, reduce the above acids to
oxides. Absorbance was measured at 500 nm. A 1 %
solution of bovine albumin was used to prepare a standard
curve.
Statistical Analysis
A statistical analysis of experimental data was performed
using a one-way or two-way ANOVA followed (if signif-
icant) by Duncan test for post hoc comparisons. For each
set of data presented in Figs. 3a, b, 4a, b, and 5a–c, two-
way ANOVA was carried out two times. First time for the
following 4 groups of rats: control, CMS-subjected,
chronically treated with IMI, CMS-subjected responding to
IMI (CMS IMI-R), and second time for the following
combination of four groups of rats: control, CMS-sub-
jected, chronically treated with IMI, CMS-subjected non-
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responding to IMI (CMS IMI-NR). The results are pre-
sented as the mean ± SEM, the differences were consid-
ered statistically significant when p\ 0.05.
Results
The Effects of Chronic Mild Stress and Imipramine
Treatment on Sucrose Consumption
For illustrative purposes, Fig. 1 shows the levels of sucrose
intake during entire period of behavioral procedure,
involving training for sucrose consumption terminated by
baseline test after six weeks of adaptation, two weeks of
stress procedure without any drug administration, and
further five weeks of stress regimen accompanied by
chronic IMI treatment.
In rats subjected to CMS for 7 weeks, sucrose intake
was significantly lower than in non-stressed animals,
amounting to 6.00 ± 0.50 versus 13.90 ± 1.7, respec-
tively, [F(1,18) = 19,885, p\ 0.005]. Administration of
IMI for 5 weeks to the animals continuously exposed to
CMS resulted in significant reduction in anhedonia, as
measured by sucrose intake, in CMS IMI-R animals and
lack of such reduction in CMS IMI-NR rats (Fig. 2).
The Effects of Chronic Mild Stress and Imipramine
Treatment on Parameters of Oxidative Stress (ROS
and MDA)
In general, for each tested parameter presented in Figs. 3, 4,
and 5, a two-way ANOVA was performed twice; in the first
variant (V1) four groups were analyzed: control, CMS, IMI,
and CMS IMI-R while in the second variant (V2) the groups:
control, CMS, IMI, and CMS IMI-NR were compared.
Regarding ROS level, this analysis calculated for V1
revealed a significant treatment effect of IMI [F(1,34) =
22.875, p\ 0.001], a lack effect of CMS application
(F = 1.376, NS) and no interaction between IMI and CMS
(F = 3.932, p = 0.055; Fig. 3a). The same analysis for V2
showed no effect of CMS (F = 0.029, NS), significant
treatment effect of IMI [F(1,34) = 17.122, p\ 0.001], and
interaction of CMS 9 IMI (F = 10.862, p\ 0.01;
Fig. 3a).
A two-way ANOVA performed for MDA levels in the
first variant showed a significant effect of IMI (F = 7.416,
p\ 0.01), lack of effect of CMS (F = 3.761, p = 0.06),
and no interaction between CMS 9 IMI (F = 3.380, NS).
The same analysis for variant 2 revealed both treatment
effect of IMI (F = 22.858, p\ 0.0001) and CMS
(F = 15.272, p\ 0.001) but no interaction of IMI 9 CMS
(F = 0.089, NS).
Altogether, the present studies indicated that application
of CMS procedure and repeated IMI administration sig-
nificantly increased ROS concentrations (by 19.5 and
41.5 %, respectively; Fig. 3a) and lipid peroxidation
assessed in liver homogenates by malondialdehyde levels
(by 56 and 67 %, respectively; Fig. 3b) compared to the
control group.
In stressed, IMI non-reactive rats, an excessive accu-
mulation of the aldehyde products of lipid peroxidation
(MDA) was found compared to their contents in control
and CMS-subjected rats (by ca. 115.5 and 38 %, respec-
tively; Fig. 3b). However, in CMS IMI-R rats, an increase
in MDA level was less pronounced (by 68 % of control and
8 % of CMS-subjected groups, Fig. 3b).
Fig. 1 Sucrose intake during
six weeks of adaptation and
seven weeks of chronic mild
stress (CMS) procedure
involving five weeks of
imipramine (IMI)
administration. Data represent
the means ± SEM; n = 7,
*p\ 0.05 versus control,
^p\ 0.05 versus CMS,
op\ 0.05 versus CMS IMI-R
Neurotox Res (2016) 30:173–184 177
123
0,0
2,0
4,0
6,0
8,0
10,0
12,0
14,0
16,0
18,0
Control CMS IMI CMS IMI-R CMS IMI-NR
su
cr
os
e 
in
ta
ke
 [g
]
* 
^ 
* O 
Fig. 2 The effect of 7-week
exposure to CMS and 5-week
treatment with IMI on the
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solution. After seven weeks of
stress and five weeks of IMI
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was statistically significantly
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The Effects of Chronic Mild Stress and Imipramine
Treatment on the Levels of Antioxidants
As to NPSH level, a two-way ANOVA performed for
variant 1 demonstrated no treatment effect of IMI
(F = 2.815, NS) and CMS application (F = 0.532, NS)
but a significant interaction of CMS 9 IMI (F = 10,711,
p\ 0.002). Similarly, for variant 2 this analysis revealed
lack of the effect of IMI (F = 0.573, NS) and CMS
(F = 0.080, NS) but a marked interaction between
CMS 9 IMI (F = 21,876, p\ 0.001).
The levels of non-protein thiols (NPSH), mainly repre-
sented by GSH were significantly increased in groups
subjected to CMS (by 31 %) or chronic IMI treatment (by
25.3 %) compared to that in control group. In the CMS
IMI-R, only a small non-significant increase in NPSH level
(15 % of control) was observed while in CMS IMI-NR
animals it was significantly decreased in comparison to
CMS and IMI-treated groups (Fig. 4a).
A two-way ANOVA performed for SS levels in the first
and second variants revealed significant effects of CMS
application (F = 20.917, p\ 0.001 and F = 13.797,
p\ 0.001, respectively) and chronic IMI treatment (F =
5.7, p\ 0.05 and F = 11.854, p\ 0.01, respectively) and
a lack of interactions CMS 9 IMI (F = 0.063, NS and
F = 1.552, NS, respectively).
Application of CMS induced a marked increase in SS
content (by ca 25 % of control) while chronic IMI treat-
ment decreased it in a non-statistically significant manner
(by 11 % of control). In the CMS IMI-R, a significant
increase in SS content (by 25 % of IMI-treated group) was
observed while in CMS IMI-NR rats, its level was slightly
but non-significantly elevated (by 14 % of IMI-treated
group) and significantly decreased in comparison to CMS-
subjected rats (Fig. 4b).
The Effects of Chronic Mild Stress and Imipramine
Treatment on Activity of Antioxidant Enzymes
There was no significant effect of chronic IMI adminis-
tration and/or CMS procedure on SOD activity in the rat
liver (Fig. 5a).
A two-way ANOVA performed for GPx activity in the
rat liver showed in the first variant a significant effect of
chronic IMI treatment (F = 6.111, p\ 0.02), a lack of
effect of CMS (F = 2.423, NS), and no interaction
between CMS 9 IMI (F = 1.709, NS). The same analysis
for variant 2 revealed only a significant interaction of
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Fig. 5 The effect of 7-week exposure to CMS and 5-week IMI
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CMS 9 IMI (F = 8.544, p\ 0.01) but a lack of effects of
CMS procedure (F = 0.053, NS) and chronic IMI treat-
ment (F = 0.398, NS).
Both CMS and chronic IMI treatment increased GPx
activity (by 47 and 62 % of control, respectively). In the
CMS IMI-R rats, the activity of this enzyme was still
significantly enhanced (by 66 % of control). On the other
hand, in the CMS IMI-NR rats, a significant decrease in
GPx activity was observed compared to rats subjected to
chronic IMI treatment or to rats subjected to CMS reactive
to IMI (by 27 and 34 %, respectively) (Fig. 5b).
A two-way ANOVA performed for CAT activity in the
rat liver showed in the first variant significant effects of
CMS (F = 4.709, p\ 0.05) and chronic IMI treatment
(F = 11.073, p\ 0.06) and an interaction of CMS 9 IMI
(F = 5.075, p\ 0.05). The same analysis for variant 2
revealed only a significant interaction of CMS 9 IMI
(F = 16.625, p\ 0.001) but lack of the effects of CMS
procedure (F = 0.467, NS) and chronic IMI treatment
(F = 3.733, p = 0.06).
Similarly as in the case of GPx, CMS and chronic IMI
treatment increased CAT activity (by 61 and 77 % of
control, respectively). In the CMS IMI-R rats, the activity
of this enzyme was still significantly enhanced (by 76 % of
control) while in CMS IMI-NR rats it was markedly
decreased compared to group of non-stressed rats receiving
chronic IMI (by 25 %) (Fig. 5c).
Discussion
The present studies confirmed that CMS procedure models
one of the main symptom of depression, namely anhedonia,
and administration of IMI for 5 weeks to the animals still
subjected to CMS resulted in a significant reduction in
anhedonia in a majority of animals (Papp and Moryl 1994;
Kubera et al. 1996), although, as it was described by some
of us earlier, about 20 % of animals did not respond to the
IMI treatment by reversal of CMS-induced decrease in
sucrose intake (Faron-Górecka et al. 2014). Clinically, the
persistence of anhedonia is one of the most treatment-re-
sistant symptoms of major depression. In humans, only
47–52 % of patients with major depression positively
responded to an initial antidepressant medication (Rush
et al. 2011).
In depressed patients, total oxidative status, oxidative
stress index, and markers of lipid peroxidation are
increased in plasma, serum, or urine (Smaga et al. 2015).
MDA levels were particularly high in patients diagnosed
with recurrent depressive disorder compared to patients
suffering from the first episode (Stefanescu and Ciobica
2012; Rybka et al. 2013; Lopresti et al. 2014). Post-mortem
studies revealed increased lipid peroxidation in the anterior
cingulated cortex of depressed patients (Wang et al. 2009).
Decreased antioxidant status in depression, characterized
by a significantly reduced level of non-enzymatic antioxi-
dant molecules, such as tryptophan, tyrosine, vitamin E,
ascorbic acid, alfa-tocopherol, zinc, and GSH (Kodydková
et al. 2009; Maes et al. 2011a), is usually connected with a
fall in GPx, CAT, and SOD activity in blood although in
some other studies an increase or no differences in GPx and
SOD activity were described (Bilici et al. 2001; Galecki
et al. 2009; Rybka et al. 2013; Smaga et al. 2015).
Clinical studies of the effect of antidepressant drugs on
oxidative biomarkers also have not brought unequivocal
results. The studies of oxidative biomarkers in patients
suffering from drug-resistant depression are limited to
determination of the level of the antioxidant coenzyme Q10
(Maes et al. 2009). For obvious reasons, there are also no
data on changes in antioxidant system function in the liver
of depressed patients treated with antidepressant drugs.
Therefore, we decided that it would be significant to carry
out such studies in an experimental model of depression
including the animals non-responding to the antidepressant
action of IMI.
The above-mentioned clinical data are in line with results
of the present study, which showed that rats subjected to
CMS, a well-described animal model of depression, showed
higher production of ROS and enhanced lipid peroxidation in
the liver. These changes could lead to an adaptive response
reflected by mobilization of antioxidant defense system i.e.,
by elevation of NPSH and SS levels as well as increase in
GSH peroxidase and catalase activity in this tissue. The
studies conducted so far most often examined lipid peroxi-
dation in different animal models of depression and were
focused on brain structures. All those studies reported an
increase in this parameter (Smaga et al. 2015). The CMS-
induced increase in ROS and lipid peroxide level in the liver
might be correlated with similar oxidative changes in brain
structures reported by other authors who used the same ani-
mal model of depression (Lucca et al. 2009a, b). Furthermore,
Zafir and Banu (2007) using the restraint stress model found
an enhanced lipid peroxidation level not only in the brain but
also in the liver of the stressed animals.
Surprisingly, in the present study, chronic IMI treatment
resulted in similar changes in both oxidative stress
parameters and antioxidant mechanism as those evoked by
the CMS, but no additive effect was observed when these
two procedures were combined in IMI responding rats. The
lack of additive effects of CMS and chronic IMI treatment
on oxidative stress and antioxidant defense system in the
liver suggests involvement of a common mechanism
although this mechanism is unknown. The increase in
MDA level was almost identical in CMS group, IMI group,
and in CMS IMI-R group, whereas in CMS IMI-NR group,
the level of MDA was significantly higher than in rats
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subjected to CMS. The latter effect was probably due to
summing of the pro-oxidative effects of CMS and IMI
resulting from the stress-induced activation of hypothala-
mic—pituitary—adrenal (HPA) axis and sympathetic—
adrenal—medullary (SAM) axis and IMI-induced increase
in peripheral level of serotonin and noradrenaline. The
abnormal release of corticosteroids induces production of
ROS under stress conditions (Madrigal et al. 2006; Lin
et al. 2004), whereas monoaminooxidase (MAO) present in
hepatocytes by deamination of monoamines also generates
high number of free radicals (Wąsik et al. 2013; Antkie-
wicz-Michaluk et al. 2014). Removal and metabolic
degradation of catecholamines by the liver plays a major
role in the elimination of these amines from the circulation.
Before being metabolized by enzymes inside hepatocytes,
catecholamines must enter the cells, and ex vivo studies
showed that IMI and its metabolite desipramine did not
inhibit monoamine uptake by hepatocytes (Martel et al.
1998). In CMS IMI-R rats, the above-mentioned additive
effect is not observed probably due to the inhibitory action
of IMI on the HPA axis (Dhingra and Bansal, 2015) which
eliminates stimulatory effect of glucocorticoids on the
production of ROS.
In opposite to our results for the liver, Melzacka et al.
(1995) and Reus et al. (2010) observed reduction in lipid
peroxidation in the studied brain structures after acute and
chronic IMI administration. Moreover, Zafir et al. (2009)
showed that IMI normalized the accumulation of lipid
peroxidation product (measured by malondialdehyde level)
increased in the brain in response to exposure of animals to
stress. On the other hand, Omar et al. (2011) and Abdel-
Salam et al. (2013) observed that IMI pretreatment sig-
nificantly increased brain lipid peroxidation induced by
thioacetamide or lipopolysaccharide (LPS) administration
and this effect was IMI dose-dependent.
In clinical practice, a prolonged treatment with antide-
pressants reduced MDA level, however, this observation
was performed for selective serotonin reuptake inhibitors
(SSRI) (Bilici et al. 2001; Khanzode et al. 2003; Galecki
et al. 2009) not for IMI; moreover, no such change was
observed after shorter treatment period with venlafaxine,
reboxetine, or sertraline (Sarandol et al. 2007).
The sum of low molecular weight thiols (in reduced
form), such as GSH, homocysteine, cysteine, and cys-
teinylglycine is referred to as non-protein sulfhydryl groups
(Bilska-Wilkosz et al. 2013). Sulfane sulfur is defined as a
labile, exceptionally reactive sulfur atom which can easily
leave structure of sulfane sulfur-containing compounds and
has properties of a ROS scavenger (Bilska-Wilkosz et al.
2013). The present studies showed that chronic stress
affects sulfur metabolism, significantly increasing hepatic
production of SS and NPSH, whereas chronic IMI
administration to CMS IMI-NR, but not to CMS IMI-R
rats, decreased the level of these two protective compounds
in comparison to chronically stressed rats.
GSH peroxidase catalyzes the reduction of hydrox-
yperoxides by GSH and its main function is to protect the
cell against the damaging effect of endogenously formed
hydroxyperoxides. Enzymatic activity of GPx was induced
by IMI, regardless of whether it was applied to unstressed
or stressed animals, although CMS IMI-NR animals did not
show an increase in GPx activity. Our observations are
partially in agreement with those of Djordjevic et al. (2011)
who showed that chronic fluoxetine administration, like
chronic IMI administration in our study, increased GRx
activity in the liver in chronically stressed fluoxetine-re-
sponding and unstressed animals. The increase in GPx
activity emerges as a compensatory response to the
enhanced lipid peroxidation since GPx scavenges primarily
lipid peroxides (Djordjevic et al. 2011). The increased lipid
peroxidation in CMS IMI-NR rats above the level observed
in CMS IMI-R rats may be connected with the lack of
increase in GPx activity in these animals.
In clinical studies in depressed patients after treatment
with antidepressants, a decrease, an increase, or no dif-
ferences in GPx level were observed (Bilici et al. 2001;
Galecki et al. 2009; Rybka et al. 2013). The lack of the
CAT activity increase in CNS IMI-NR animals, in contrast
to all remaining groups, observed in our studies, like the
above-described lack of GPx activity elevation, can be one
of causes to drug-resistance, although this suggestion
requires further studies.
In our former studies on immunity of rats resistant to
antidepressant effect of IMI, we found a significant
increase in IFN-c and IL-6 synthesis by spleen cells of
these animals as well as increase in inflammatory cytokine
expression, including IL-6, in the hippocampus and pre-
frontal cortex in comparison to CMS IMI-R rats. On the
other hand, it is established that pro-inflammatory cytoki-
nes, including IL-6, aggravate the oxidative damage of the
vital organs, particularly the liver (Sundaram et al. 2014;
Zhou et al. 2015). Kayanoki et al. (1994) showed that IL-6
suppressed catalase gene expression in cultured rat hepa-
tocytes. It has also been shown that inhibition of CAT
activity by IL-6 is nitric oxide-dependent by interaction of
nitric oxide with the heme group of CAT and it was pro-
posed that this inhibition might increase susceptibility to
cytokine- or nitric oxide-induced cell killing (Sigfrid et al.
2003).
In the light of the above observations, we believe that
the decrease in CAT activity in CMS IMI-NR rats com-
pared with CMS IMI-R animals, described in the present
paper, may be connected with the observed increase in pro-
inflammatory cytokine level in these animals.
In the present study, we did not observe changes in SOD
activity in any of the studied groups. On the other hand,
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Djordjevic et al. (2011) observed down-regulation of SOD
activity after fluoxetine treatment in the brain of both
stressed and non-stressed animals, whereas other authors
reported that treatment with fluoxetine or IMI could pre-
vent stress-induced reduction of SOD activity in the brain
and liver (Zafir and Banu 2007; Zafir et al. 2009). SOD
plays a predominant role in scavenging superoxide anion
transforming it into hydrogen peroxide. Even though the
activity of SOD is not changed after chronic IMI and/or
chronic stress application, our results showed an increase in
activity of the hydrogen peroxide-metabolizing enzymes,
like catalase and GSH peroxidase.
In clinical reports, the effect of antidepressant drug
treatment on SOD activity is not clear. SOD activity was
lowered (Djordjevic et al. 2011), not changed (Kotan et al.
2011), or increased (Herken et al. 2007) in patients treated
with antidepressant drugs.
In summary, taking into account the results of behav-
ioral studies described in the present paper, we suggest that
oxidative stress and antioxidant system in the liver, in
contrast to the brain (Liu et al. 1996; Lucca et al. 2009a, b;
Mo _zd _zeń et al. 2014), are not directly connected with
anhedonia and antidepressant effect of IMI. In opposite to
our expectation, the CMS-induced hepatic oxidative stress
was not prevented by the IMI administration. CMS induced
similar destructive changes in oxidative system in the liver
as chronic administration of IMI to control or stressed
animals. This investigation revealed that the restorative
actions of IMI as evidenced by the reduction of anhedonia
in CMS IMI-R rats were accompanied by the increase in
ROS level and lipid peroxidation, and similar increase in
both these destructive parameters was observed also as a
result of CMS or chronic IMI administration to control
animals. Moreover, in chronically stressed and IMI-treated
animals which did not respond to antidepressant activity of
IMI, MDA level was increased in comparison to CMS rats,
activity of antioxidant enzymes (GPx and CAT) was
decreased in comparison to animals chronically treated
with IMI, whereas levels of two protective compounds SS
and NPSH were decreased in comparison to chronically
stressed rats. At present, there is no direct answer to the
question whether low reactivity of antioxidant system in
the liver of the non-responder group could participate, at
least partly, in the mechanism of resistance to IMI.
In the present study, we evidenced a pro-oxidant action
of IMI on the liver, particularly evident in IMI non-re-
sponding rats. This poses the question about a disadvan-
tageous action of this drug not only in depression but also
in comorbid diseases. The clinical significance of this
observation remains to be established, especially because
IMI is used for therapy of enuresis in children, and in view
of the fact that antidepressant drugs are used for the
treatment of depression in patients, with comorbid cancer
or neurological and/or cardiologic diseases underlain, like
depression, by oxidative stress, and in patients with hep-
atitis C viral infection, particularly those treated with
interferon alpha/ribavirin combination therapy (Abdel
Salam et al. 2013).
The obtained results suggest that IMI therapy in patients
resistant to this drug should be discontinued immediately
because it is dangerous to the correct functioning of the
liver.
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